Figure 5.
BV6/DAC cotreatment induces caspase-independent cell death in apoptosis-resistant AML cells. (a) AML cells were treated for 48 h (NB4, MonoMac6) or 6 h (MV4-11, Molm-13) with BV6 and DAC in the presence or absence of 20 μM zVAD.fmk (MV4-11: 600 nM BV6, 30 nM DAC; NB4: 100 nM BV6, 50 nM DAC; Molm13: 400 nM BV6, 100 nM DAC; MonoMac6: 3 μM BV6, 300 nM DAC); treatment with 40 ng/ml MFL, a hexameric form of CD95 ligand, for 48 h served as positive control. Cell death was determined by FSC/SSC analysis. Mean and SD of three experiments performed in triplicate are shown; *P<0.05; **P<0.01. (b and c) AML cells were treated for 6 h with BV6 and DAC in the presence or absence of 20 μM zVAD.fmk (MV4-11: 600 nM BV6, 30 nM DAC; Molm13: 400 nM BV6, 100 nM DAC). Cell death was determined by Annexin-V/PI staining and fluorescence-activated cell sorting analysis. The percentage of Annexin-V positive/PI double-positive cells is shown (b) with mean and SD of three experiments performed in triplicate; **P<0.01. In c, the percentage of Annexin-V (A)- and/or PI (P)-positive and -negative cells is shown with mean and SD of three experiments performed in triplicate